-
Mashup Score: 0
The DOJ has accused CHEST and other medical journals of scientific bias, demanding responses to a list of questions by May 2, 2025.
Source: www.empr.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Clinical Challenge: Rash on Chest and Arms - 2 day(s) ago
A 19-year-old Hispanic man is referred for treatment of a minimally pruritic rash affecting his chest and upper arms. Can you make the correct diagnosis?
Source: www.empr.comCategories: General Medicine NewsTweet
-
Mashup Score: 0RFK Jr.'s Major Autism Study to Use Private Health Records - 2 day(s) ago
Meanwhile, a new registry is being created to track those with autism, and that information will be part of the database.
Source: www.empr.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
BA-102 is an investigational agent that aims to target and regulate nitric oxide (NO) levels in the brain.
Source: www.empr.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
The plan would cut tens of billions of dollars from federal health spending and move many already existing agencies into a new department called the Administration for a Healthy America.
Source: www.empr.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 0
The open-label, randomized ASCENT-04/KEYNOTE-D19 study included 443 patients with previously untreated, inoperable locally advanced or metastatic TNBC whose tumors express PD-L1.
Source: www.empr.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).
Source: www.empr.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Pfizer’s Abrysvo and GSK’s Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.
Source: www.empr.comCategories: General Medicine NewsTweet
-
Mashup Score: 0MPR Weekly Dose Podcast #233 - 7 day(s) ago
Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears smart belt device reduce fall injury.
Source: www.empr.comCategories: General Medicine NewsTweet-
👂 New MPR Pod! This week: 🔸 Pfizer ends program for obesity Tx; 🔹 FDA warns about counterfeit Ozempic; 🔸 Daily pill shows promise for reducing HbA1c; 🔹 Mavacamten misses in nonobstructive HCM trial; and 🔸 FDA clears smart belt to reduce fall injury. https://t.co/u3aAcMQAd1 https://t.co/DH5UBd3GRG
-
-
Mashup Score: 0
Orforglipron is an oral, once-daily glucagon-like peptide-1 receptor agonist.
Source: www.empr.comCategories: General Medicine NewsTweet
In an unusual step, the Interim US Attorney for the District of Columbia, Edward Martin Jr., has accused the scientific journal CHEST of bias. https://t.co/l161b4cqPF